2011 Update: antigen-specific therapy in type 1 diabetes.
2011 Update: antigen-specific therapy in type 1 diabetes.
复制标题
DOI：
10.1097/med.0b013e32834803ae
复制
发表时间：
2011-08
期刊：
影响因子：
--
通讯作者：
von Herrath M
中科院分区：
文献类型：
--
作者：
Michels AW;von Herrath M
Update on the clinical trials using antigen specific therapies in autoimmune diabetes. Type 1 diabetes is now a predictable disease with the measurement of islet autoantibodies, and the incidence is increasing dramatically. Safe and effective interventions are needed to stop the underlying autoimmune destruction of insulin producing beta cells. Beta cell antigens, insulin and glutamic acid decarboxylase, are being used to preserve endogenous insulin production in individuals with new onset diabetes and to prevent diabetes. The results of antigen specific immune intervention trials are reviewed and consideration is given to future directions for inducing tolerance in type 1 diabetes. Antigen specific immune therapies act by enhancing regulatory T cell function, in animal models often locally and selectively in islets or pancreatic lymph nodes, while inhibiting effector T cells. This therapeutic pathway provides a safe treatment to preserve beta cell function in new onset diabetic individuals with the GAD-Alum vaccine being the most extensively studied therapy. Insulin is being used in many forms to prevent diabetes and stop the underlying autoimmune process. For the future, combination immune therapies targeting different pathways in the immune system will be needed to effectively induce sustained tolerance in type 1 diabetes.
